Jonathan R. Strosberg, MD
Lutathera (lutetium Lu 177 dotatate) has demonstrated “quite striking” results with a favorable safety profile as a therapy for patients with progressive midgut neuroendocrine tumors (NETs) in the first randomized phase III study to evaluate a radiolabeled somatostatin analogue in this treatment setting, according to a leading researcher.
Pivotal Trial Details
The NETTER-1 study enrolled patients with inoperable, well-differentiated, somatostatin receptor–positive NETs of the small intestine or distal colon (midgut carcinoid tumors) who had progressed after standard-dose octreotide LAR (30 mg) therapy.
... to read the full story